Hyaluronic acid levels can predict risk of serious liver events in people living with HIV and hepatitis B or C co-infection

Michael Carter
Published: 17 June 2013

A simple blood test can predict the risk of liver-related death or hepatic encephalopathy for people living with HIV who have hepatitis B or hepatitis C co-infection, investigators from the EuroSIDA cohort report in PLoS One.

Their results showed that baseline elevations in plasma levels of hyaluronic acid (HA) were associated with a significant increase in the risk of serious liver-related events. Levels of this biomarker remained stable in people who remained 'event free', but increased in those experiencing disease progression.

“The present study indicates that HA could be a useful biomarker to estimate the long-term risk of liver disease,” write the authors.

Many people with HIV have viral hepatitis co-infections and liver disease related to hepatitis B virus (HBV) or hepatitis C virus (HCV) is now an important cause of serious illness and death in people with these co-infections.

Traditionally, liver biopsy has been the 'gold standard' for diagnosing and monitoring liver disease. However, it is uncomfortable, can lead to complications and is unpopular with patients. Therefore, non-invasive tests are increasingly being used to monitor liver disease. These investigations can accurately assess the extent of liver fibrosis in people with co-infections, but their ability to predict the risk of disease progression is currently unknown.

A potential biomarker is hyaluronic acid. It can be measured during routine care using a simple and cheap blood test.

The clearance of hyaluronic acid is impaired in people with liver disease. Research in people who have viral hepatitis mono-infection has shown that elevations in hyaluronic acid are associated with an increased risk of serious liver-related events. Investigators wanted to see if this was also the case in people with HIV and viral hepatitis co-infections.

The study sample included 1252 people enrolled in the EuroSIDA cohort.

Normal hyaluronic acid levels are between 0-75ng/ml. The median baseline value for all participants in the study was well within this range at 33.9ng/ml. It was higher in people with chronic HCV (37.7ng/ml), than in people with chronic HBV (31.4ng/dl) and people who had had cleared their HCV infection (27.5ng/ml).

Participants in the study were followed-up for a median of 8.2 years. During this time there were 84 serious liver-related events (7%; 52 liver-related deaths and 32 hepatic encephalopathy).

The median baseline hyaluronic acid level was 221.6ng/ml among people experiencing a liver-related event compared to 31.8ng/ml for people whose disease did not progress.

Participants were divided into three groups according to whether their baseline hyaluronic acid levels were within the normal range, mildly elevated (75-250ng/ml) or markedly elevated (above 250ng/ml).

People with normal levels had a 1% five-year risk of a liver-related event. This compared to a 12% risk for individuals with moderate elevations and a 45% risk for those with markedly elevated hyaluronic acid (p < 0.001).

After controlling for potential confounders, the investigators found that, compared to people with normal hyaluronic acid values, participants with moderate elevations had a five-fold increase in the risk of liver-related events (IRR = 5.22; 95% CI, 2.86-9.26, p = 0.0007), while those with marked elevations had an almost 30-fold increase in the risk of an event (IRR = 28.22; 95% CI, 14.95-46,00, p < 0.0001).

Hyaluronic acid remained stable in people who did not experience an event, increasing by a median of 1ng/ml per year. In contrast, the participants who developed serious liver-related events experienced median annual increases of 111.1ng/ml (p < 0.0001).

“This large cohort study demonstrates that baseline HA was a strong predictor of later hepatic encephalopathy or liver-related death in HIV-1 patients co-infected with HBV and/or HCV. Patients, who during follow-up experienced a liver-related event, had higher annual increases in HA compared to patients without an event,” conclude the researchers. “Plasma HA may be useful, either alone or in combination with other non-invasive markers, to monitor progression of liver disease and risk of complications in patients with chronic viral hepatitis.”

Reference

Peters L et al. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS One, 8:5. e64283, 2013.

Hepatitis information

For more information on hepatitis visit infohep.org.

Infohep is a project we're working on with the World Hepatitis Alliance and the European Liver Patients Association.

Visit infohep.org >

Related news selected from other sources

More editors' picks on hepatitis and HIV >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close